欧盟的药品短缺问题从2022-2024年恶化到2022-2024年,由于供应链缺陷和监管不成体系,136种关键药品短缺。 EU drug shortages worsened from 2022–2024, with 136 critical medicines scarce due to supply chain flaws and fragmented regulations.

2022年至2024年期间,整个欧洲联盟的长期药品短缺情况恶化,根据欧盟的一项审计,有136种药品,包括抗生素、心脏病和哮喘药物,其数量极低。 Chronic drug shortages across the European Union have worsened between 2022 and 2024, with 136 medicines—including antibiotics, heart attack treatments, and asthma drugs—critically low, according to an EU audit. 比利时报告说,由于供应链的脆弱性、70%的活性成分严重依赖亚洲以及国内市场效率低下,如不同的国家定价和批准程序,造成短缺的数量最多。 Belgium reported the highest number of shortages, driven by supply chain vulnerabilities, heavy reliance on Asia for 70% of active ingredients, and internal market inefficiencies like differing national pricing and approval processes. 这些问题造成局部短缺,尽管在集团的其他地方有供应。 These issues cause localized shortages despite availability elsewhere in the bloc. 药剂师每周平均花费11小时管理短缺问题,导致病人拖延和压力。 Pharmacists spend an average of 11 hours weekly managing shortages, leading to patient delays and stress. 欧洲联盟委员会已提出一项《关键药品法》和储存战略,以促进欧盟的生产和危机准备,但在正在进行的谈判中,执行工作仍然缓慢。 The European Commission has proposed a Critical Medicines Act and stockpiling strategy to boost EU production and crisis readiness, but implementation remains slow amid ongoing negotiations.